What is Invega paliperidone used for?
Paliperidone is a medication that works in the brain to treat schizophrenia and schizoaffective disorder. It is also known as a second-generation antipsychotic (SGA) or atypical antipsychotic. Paliperidone rebalances dopamine and serotonin to improve thinking, mood, and behavior.
What does paliperidone do to the brain?
Paliperidone acts mainly by blocking the receptors for the neurotransmitters dopamine and 5-hydroxytryptamine (also called serotonin), which are involved in schizophrenia. By blocking these receptors, paliperidone helps to normalise the activity of the brain and reduce symptoms.
Is paliperidone a sedative?
Paliperidone’s activity profile suggests that it has the potential to cause orthostatic hypotension, weight gain, and sedation. However, because it has no antagonistic activity at cholinergic receptors, it has a low propensity to cause anticholinergic adverse effects and cognitive impairment.
What are the side effects of the medication Invega?
Drowsiness, dizziness, lightheadedness, drooling, stomach/abdominal pain, weight gain, or tiredness may occur. If any of these side effects persist or worsen, tell your doctor promptly. Dizziness and lightheadedness can increase the risk of falling.
How does Invega work to deliver paliperidone?
INVEGA® uses osmotic pressure to deliver paliperidone at a controlled rate. The delivery system, which resembles a capsule-shaped tablet in appearance, consists of an osmotically active trilayer core surrounded by a subcoat and semipermeable membrane.
How is Invega used in the treatment of schizophrenia?
INVEGA® (paliperidone) Extended-Release Tablets are indicated for the treatment of schizophrenia[seeClinical Studies]. The efficacy of INVEGA® in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents, as well as one maintenance trial in adults. Schizoaffective Disorder
Which is the active ingredient in Invega extended release tablets?
Paliperidone, the active ingredient in INVEGA® Extended-Release Tablets, is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives. INVEGA® contains a racemic mixture of (+)-and (-)-paliperidone.
When was the new formulation of paliperidone approved?
On May 18, 2015, a new formulation of paliperidone palmitate was approved by the FDA under the brand name Invega Trinza. A similar 3 -monthly injection of prolonged release suspension was approved in 2016 by the European Medicines Agency originally under the brand name Paliperidone Janssen, later renamed to Trevicta.
